GO:0038046 G protein-coupled enkephalin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038046 describes the molecular function of binding an enkephalin pentapeptide and transmitting the signal across the membrane by activating an associated G-protein.
• The term is synonymous with delta-opioid receptor activity and enkephalin receptor activity, and is a molecular_function in the Gene Ontology.
• Enkephalins are endogenous pentapeptides (Tyr-Gly-Gly-Phe-Met or Tyr-Gly-Gly-Phe-Leu) that regulate nociception.
• The receptor is a seven-transmembrane G protein-coupled receptor that couples primarily to Gi/o proteins to inhibit adenylyl cyclase and modulate ion channels [1,4].
• Post-translational modifications, biased agonism, and receptor phosphorylation regulate signaling and are active areas of drug discovery [3,5].
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential for dissecting enkephalin receptor function in pain, addiction, and cardioprotection [1,7].
Description
G protein-coupled enkephalin receptor activity (GO:0038046) is a molecular function that combines with an enkephalin pentapeptide and transmits the signal across the membrane by activating an associated G-protein. Enkephalins are endogenous opioid peptides that regulate nociception in the body, and their receptors are central to pain processing and opioid pharmacology [1,2]. This GO term captures the specific activity of the delta-opioid receptor, one of the three classical opioid receptor types, and is essential for understanding how endogenous opioid peptides modulate neuronal excitability. Researchers study this activity to dissect analgesic mechanisms, opioid tolerance, addiction, and off-target effects of opioid drugs [1,3]. The receptor's ability to couple to multiple downstream effectors and its regulation by post-translational modifications make it a rich target for functional genomics and drug discovery [5,6]. Understanding GO:0038046 at the molecular level informs the development of safer analgesics and provides a framework for investigating GPCR signaling in native contexts [3,6].
G protein-coupled enkephalin receptor activity At A Glance
| GO ID | GO:0038046 |
|---|---|
| GO term | G protein-coupled enkephalin receptor activity |
| Ontology | molecular_function |
| Synonym | delta-opioid receptor activity; enkephalin receptor activity |
| Major function | Binding enkephalin pentapeptides and activating an associated G-protein to transmit a signal across the membrane |
| Ligand | Enkephalin pentapeptides: Tyr-Gly-Gly-Phe-Met or Tyr-Gly-Gly-Phe-Leu |
| Receptor class | Class A (rhodopsin-like) G protein-coupled receptor |
| Primary G-protein coupling | Gi/o family, leading to inhibition of adenylyl cyclase and modulation of ion channels |
| Tissue distribution | Widely expressed in the central and peripheral nervous systems, with roles in pain, reward, and cardioprotection |
What Is GO:0038046?
In our own words, GO:0038046 describes the function of a receptor that binds enkephalin peptides and, upon binding, activates an associated G-protein to transmit a signal across the cell membrane. This activity is synonymous with delta-opioid receptor activity and enkephalin receptor activity. The enkephalins are pentapeptides with the sequences Tyr-Gly-Gly-Phe-Met (met-enkephalin) or Tyr-Gly-Gly-Phe-Leu (leu-enkephalin) that regulate nociception. The receptor itself is a G protein-coupled receptor (GPCR) that couples to heterotrimeric G-proteins, typically Gi/o, leading to downstream modulation of effectors such as adenylyl cyclase and ion channels [1,4].
Why Is G protein-coupled enkephalin receptor activity Important in Cell Biology?
GO:0038046 is important because it defines the molecular activity of a key opioid receptor that mediates the physiological effects of endogenous enkephalins, including analgesia, reward, and stress responses [1,2]. Dysregulation of this activity contributes to pain chronification, opioid tolerance, addiction, and mood disorders [1,3]. Moreover, the receptor is a validated drug target for pain management, and understanding its signaling bias and regulation can lead to safer therapeutics with fewer side effects [3,5]. In cardiovascular research, enkephalin receptor activity has been implicated in opioid-induced cardioprotection. Thus, studying this GO term bridges basic GPCR biology with translational opportunities in pain, addiction, and cardiology [1,7].
• Mediates endogenous analgesia and modulates nociceptive signaling in the spinal cord and brain [1,8].
• Plays a role in reward, addiction, and emotional regulation through interactions with dopaminergic systems [1,2].
• Is a target for opioid analgesics and biased ligands aimed at separating analgesia from side effects.
• Regulates ion channels and neurotransmitter release, influencing neuronal excitability [1,4].
• Is subject to post-translational modifications that alter receptor trafficking and signaling.
• Contributes to opioid-induced cardioprotection and ischemic preconditioning.
• Serves as a model for studying GPCR oligomerization and proximal proteome dynamics.
• Informs the development of CRISPR-based disease models for pain and addiction research [1,3].
Molecular Mechanism of G protein-coupled enkephalin receptor activity
Ligand binding and receptor activation
In simple terms: Enkephalin binds to the receptor like a key in a lock, causing the receptor to change shape.
Enkephalin pentapeptides bind to the orthosteric pocket of the delta-opioid receptor, a class A GPCR, triggering conformational changes in the transmembrane helices that lead to receptor activation [1,4]. This binding is highly specific and involves interactions with conserved residues in the binding pocket. The activated receptor then acts as a guanine nucleotide exchange factor for the associated G-protein.
G-protein coupling and nucleotide exchange
In simple terms: The activated receptor turns on a G-protein by swapping its GDP for GTP.
Upon activation, the receptor catalyzes the exchange of GDP for GTP on the G-alpha subunit of the heterotrimeric G-protein, primarily Gi/o family members [1,4]. This leads to dissociation of the G-alpha-GTP complex from the G-beta-gamma dimer, both of which can then modulate downstream effectors.
Downstream effector modulation
In simple terms: The G-protein subunits then send signals inside the cell, such as reducing cyclic AMP or opening ion channels.
The G-alpha-i subunit inhibits adenylyl cyclase, decreasing cyclic AMP levels, while the G-beta-gamma dimer can activate G protein-gated inwardly rectifying potassium (GIRK) channels and inhibit voltage-gated calcium channels [1,4]. These events reduce neuronal excitability and neurotransmitter release, contributing to analgesia [1,8].
Receptor phosphorylation and desensitization
In simple terms: After signaling, the receptor gets tagged with phosphate groups, which can turn it off or make it internalize.
Activated receptors are phosphorylated by G protein-coupled receptor kinases (GRKs), promoting arrestin recruitment, desensitization, and internalization. This process is a key regulatory mechanism that prevents excessive signaling and contributes to tolerance.
Biased signaling and functional selectivity
In simple terms: Different ligands can make the receptor signal through some pathways more than others.
Biased agonists can preferentially activate G-protein-mediated pathways versus arrestin-mediated pathways, offering a strategy to separate analgesic effects from side effects such as respiratory depression and constipation. The molecular basis involves ligand-specific receptor conformations and distinct downstream phosphorylation patterns [3,5].
Key Genes Involved in GO:0038046 G protein-coupled enkephalin receptor activity
The following genes and proteins are central to G protein-coupled enkephalin receptor activity, including the receptor itself, its endogenous ligands, and key signaling and regulatory components.
| Gene | Major Role | Research Relevance |
|---|---|---|
| OPRD1 | Encodes the delta-opioid receptor, the primary receptor for enkephalins | Target for knockout, knock-in, and point-mutation studies of enkephalin signaling |
| PENK | Encodes proenkephalin, the precursor for met- and leu-enkephalin | Knockout models to study endogenous enkephalin function |
| OPRM1 | Encodes the mu-opioid receptor, which also binds enkephalins with lower affinity | Comparative studies of opioid receptor specificity |
| OPRK1 | Encodes the kappa-opioid receptor, a related opioid receptor | Research on opioid receptor family diversity |
| GNAI1 | Encodes G-alpha-i1 subunit, a primary G-protein coupled to delta-opioid receptor | Knockout and point-mutation to dissect G-protein coupling |
| GNAI2 | Encodes G-alpha-i2 subunit, another Gi/o family member | Studies of G-protein redundancy and specificity |
| GNAI3 | Encodes G-alpha-i3 subunit | Functional analysis of Gi/o signaling |
| GNB1 | Encodes G-beta-1 subunit of heterotrimeric G-proteins | Investigation of G-beta-gamma-mediated effects |
| GNG2 | Encodes G-gamma-2 subunit | Research on G-beta-gamma dimer signaling |
| ARRB1 | Encodes beta-arrestin-1, involved in receptor desensitization and biased signaling | Knockout models to study arrestin-mediated pathways |
| ARRB2 | Encodes beta-arrestin-2 | Studies of receptor internalization and tolerance |
| GRK2 | Encodes G protein-coupled receptor kinase 2, phosphorylates activated receptors | Point-mutation and knockout to assess desensitization |
| GRK3 | Encodes G protein-coupled receptor kinase 3 | Research on receptor phosphorylation specificity |
| KCNJ3 | Encodes GIRK1, a G protein-gated potassium channel subunit | Knockout to study downstream effects on excitability |
| KCNJ6 | Encodes GIRK2 | Functional studies of G-beta-gamma-mediated channel activation |
| CACNA1B | Encodes N-type calcium channel, inhibited by G-beta-gamma | Research on neurotransmitter release modulation |
| ADCY1 | Encodes adenylyl cyclase type 1, inhibited by G-alpha-i | Studies of cyclic AMP signaling |
| SRC | Encodes Src kinase, involved in opioid receptor signaling | Investigation of non-canonical signaling pathways |
How Is G protein-coupled enkephalin receptor activity Regulated?
G protein-coupled enkephalin receptor activity is regulated at multiple levels. Post-translational modifications, including phosphorylation by GRKs and ubiquitination, control receptor desensitization, internalization, and recycling. The proximal proteome of activated opioid receptors reveals dynamic interactions with trafficking and signaling proteins that shape the response. Biased ligands can stabilize distinct receptor conformations, altering the balance between G-protein and arrestin pathways. Additionally, heteromerization with other opioid receptors and interactions with scaffolding proteins modulate signaling [1,4]. These regulatory mechanisms are critical for understanding tolerance, dependence, and the development of safer analgesics [3,5].
G protein-coupled enkephalin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OPRD1 | Chronic pain, addiction, mood disorders | Knockout and point-mutation cell lines; knock-in mice |
| PENK | Pain sensitivity, stress response | Overexpression and knockout models |
| ARRB1 | Opioid tolerance, biased signaling | Knockout and point-mutation to block arrestin recruitment |
| GRK2 | Desensitization, heart failure | Knockout and kinase-dead knock-in |
| KCNJ6 | Pain, neuronal excitability | Knockout and overexpression for electrophysiology |
Pain and analgesia
Enkephalin receptor activity is central to endogenous pain control. Activation of delta-opioid receptors by enkephalins produces analgesia in animal models, and dysregulation contributes to chronic pain states [1,8]. Targeting this receptor with biased agonists may provide pain relief with fewer side effects than mu-opioid receptor agonists.
Addiction and reward
Opioid receptors, including the delta-opioid receptor, modulate reward circuitry and are implicated in addiction to opioids and other drugs of abuse [1,2]. Enkephalin signaling in limbic regions influences drug-seeking behavior and emotional responses.
Cardioprotection
Opioid-induced cardioprotection involves delta-opioid receptor activation, which can protect the heart against ischemia-reperfusion injury. Enkephalin receptor activity is therefore a potential target for cardioprotective therapies.
Neurological and psychiatric disorders
Alterations in enkephalin receptor signaling have been associated with mood disorders, stress responses, and neurodegenerative conditions, although the precise mechanisms are still under investigation [1,2]. Further research using CRISPR models may clarify causal roles.
From G protein-coupled enkephalin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does OPRD1 mediate enkephalin-induced analgesia? | OPRD1 knockout cell lines and mice |
| Which residues are required for G-protein coupling? | Point-mutation knock-in of OPRD1 |
| How does receptor phosphorylation affect desensitization? | Knock-in of phosphorylation-deficient OPRD1 |
| What is the role of beta-arrestin in tolerance? | ARRB1/ARRB2 knockout models |
| Can biased ligands separate analgesia from side effects? | Overexpression of OPRD1 in cell lines for signaling assays |
| How does enkephalin signaling protect the heart? | Cardiomyocyte-specific knockout of OPRD1 |
How to Study the G protein-coupled enkephalin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of receptor function | Validating OPRD1 in analgesia |
| Point-mutation knock-in | Specific residue contributions | Mapping binding pocket and coupling |
| cAMP assay | Gi-mediated inhibition of adenylyl cyclase | Ligand potency and efficacy |
| GTPγS binding | G-protein activation | Quantifying agonist activity |
| Arrestin recruitment | Biased signaling | Screening for biased ligands |
| Proximity proteomics | Protein interactions | Identifying novel regulators |
| Patch-clamp electrophysiology | Ion channel modulation | Neuronal excitability studies |
| Live-cell imaging | Receptor trafficking | Internalization and recycling dynamics |
CRISPR knockout and knock-in for receptor function
CRISPR-Cas9 can generate OPRD1 knockout cell lines to abolish enkephalin receptor activity, or knock-in specific point mutations to dissect binding and coupling domains. These models are essential for causal inference in pain and addiction research [1,3].
Signaling assays: cAMP, GTPγS, and arrestin recruitment
Functional assays such as cAMP inhibition, GTPγS binding, and arrestin recruitment measure G-protein activation and biased signaling downstream of enkephalin receptor activity [3,5]. These are used to characterize ligand efficacy and potency.
Proteomics and proximal labeling
Proximity labeling proteomics can map the proximal proteome of activated opioid receptors, revealing dynamic interactors that regulate signaling and trafficking. This approach identifies novel components of the enkephalin receptor signaling complex.
Electrophysiology and imaging
Patch-clamp electrophysiology measures GIRK channel activation and calcium channel inhibition downstream of enkephalin receptor activity [1,4]. Live-cell imaging of tagged receptors tracks internalization and recycling.
How CRISPR Can Be Used to Study GO:0038046 G protein-coupled enkephalin receptor activity
Knockout
CRISPR knockout of OPRD1 or PENK eliminates enkephalin receptor activity or its ligand, providing a clean background to test causality in pain, reward, and cardioprotection models [1,7]. Knockout cell lines are also used to validate antibody specificity and to establish baseline signaling.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can dissect the roles of specific residues in ligand binding, G-protein coupling, and phosphorylation. For example, mutating GRK phosphorylation sites can prevent desensitization and reveal their contribution to tolerance.
Knock-in
Knock-in of tagged receptors (e.g., FLAG, HA, or fluorescent proteins) enables visualization and proteomic analysis of enkephalin receptor complexes in native contexts. Knock-in of disease-associated variants can model human genetic contributions to opioid sensitivity.
Overexpression
Overexpression of OPRD1 in cell lines is used for high-throughput signaling assays and ligand screening. It also allows study of receptor pharmacology in a controlled background, complementing knockout approaches.
How EDITGENE Supports G protein-coupled enkephalin receptor activity Research
Researchers studying G protein-coupled enkephalin receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, pain modulation, or cardioprotection. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for G protein-coupled enkephalin receptor activity research.
Frequently Asked Questions About G protein-coupled enkephalin receptor activity
What is GO:0038046?
GO:0038046 is the Gene Ontology molecular function term for G protein-coupled enkephalin receptor activity, which combines with an enkephalin peptide and transmits a signal by activating an associated G-protein.
What genes are involved in G protein-coupled enkephalin receptor activity?
Key genes include OPRD1 (delta-opioid receptor), PENK (proenkephalin), GNAI1/2/3, ARRB1/2, and GRK2/3 [1,4,5].
What is the delta-opioid receptor?
The delta-opioid receptor is the protein product of the OPRD1 gene and is the primary receptor mediating enkephalin signaling, synonymous with enkephalin receptor activity [1,4].
How does enkephalin receptor signaling work?
Enkephalin binding activates the receptor, which catalyzes GDP-GTP exchange on Gi/o proteins, leading to inhibition of adenylyl cyclase and modulation of ion channels [1,4].
What diseases are associated with enkephalin receptor activity?
It is implicated in pain, addiction, mood disorders, and cardioprotection [1,2,7].
What are biased ligands for the delta-opioid receptor?
Biased ligands preferentially activate either G-protein or arrestin pathways, potentially separating analgesia from side effects.
How can CRISPR be used to study enkephalin receptors?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of receptor function in cells and animals [1,5].
What is the role of beta-arrestin in enkephalin receptor activity?
Beta-arrestin is recruited to phosphorylated receptors, mediating desensitization and internalization, and contributing to tolerance.
Is the delta-opioid receptor a good drug target?
Yes, it is a validated target for pain and other conditions, but biased agonism is being explored to improve safety.
What methods are used to measure enkephalin receptor activity?
Common methods include cAMP assays, GTPγS binding, arrestin recruitment, electrophysiology, and proteomics [3,5,6].
Conclusion
G protein-coupled enkephalin receptor activity (GO:0038046) is a fundamental molecular function that mediates the physiological effects of endogenous opioid peptides. Its regulation by phosphorylation, biased signaling, and protein interactions shapes pain, reward, and cardioprotection. CRISPR-based models are indispensable for dissecting these mechanisms and for developing safer therapeutics. EDITGENE offers comprehensive services to support this research.
References
- 1. Al-Hasani R et al.. 2011. Molecular mechanisms of opioid receptor-dependent signaling and behavior.. Anesthesiology 115(6):1363-81 PMID: 22020140
- 2. Zöllner C et al.. 2007. Opioids.. Handb Exp Pharmacol PMID: 17087119
- 3. Faouzi A et al.. 2020. Biased Opioid Ligands.. Molecules 25(18) PMID: 32948048
- 4. Waldhoer M et al.. 2004. Opioid receptors.. Annu Rev Biochem 73:953-90 PMID: 15189164
- 5. Lemos Duarte M et al.. 2020. Post-translational Modifications of Opioid Receptors.. Trends Neurosci 43(6):417-432 PMID: 32459993
- 6. Polacco BJ et al.. 2024. Profiling the proximal proteome of the activated μ-opioid receptor.. Nat Chem Biol 20(9):1133-1143 PMID: 38528119
- 7. Tanaka K et al.. 2014. Opioid-induced cardioprotection.. Curr Pharm Des 20(36):5696-705 PMID: 24502571
- 8. Kanjhan R. 1995. Opioids and pain.. Clin Exp Pharmacol Physiol 22(6-7):397-403 PMID: 8582088
